Recombinant adenovirus carrying a core neutralizing epitope of porcine epidemic diarrhea virus and heat-labile enterotoxin B of Escherichia coli as a mucosal vaccine.
Van Tan DoJisung JangJeongho ParkHoai Thu DaoKiju KimTae Wook HahnPublished in: Archives of virology (2020)
Porcine epidemic diarrhea virus (PEDV) targets the intestinal mucosa in pigs. To protect against PEDV invasion, a mucosal vaccine is utilized effectively. In this study, we generated a recombinant adenovirus vaccine encoding the heat-labile enterotoxin B (LTB) and the core neutralizing epitope (COE) of PEDV (rAd-LTB-COE). The fusion protein LTB-COE was successfully expressed by the recombinant adenovirus in HEK293 cells, and the immunogenicity of the vaccine candidate was assessed in BALB/c mice and piglets. Three intramuscular or oral vaccinations with rAd-LTB-COE at two-week intervals induced robust humoral and mucosal immune responses. Moreover, a cell-mediated immune response was promoted in immunized mice, and the neutralizing antibody inhibited both the vaccine strain and the emerging PEDV isolate. Immunization experiments in piglets revealed that rAd-LTB-COE was immunogenic and induced good immune responses in piglets. Further studies are required to evaluate the efficacy of rAd-LTB-COE against a highly virulent PEDV challenge.
Keyphrases
- immune response
- dna damage
- dna repair
- escherichia coli
- dendritic cells
- diabetic rats
- single cell
- dengue virus
- induced apoptosis
- stem cells
- ulcerative colitis
- clinical trial
- type diabetes
- randomized controlled trial
- cell free
- endoplasmic reticulum stress
- oxidative stress
- cell therapy
- gene therapy
- endothelial cells
- insulin resistance
- inflammatory response
- mesenchymal stem cells
- cell cycle arrest
- signaling pathway
- cystic fibrosis
- monoclonal antibody
- irritable bowel syndrome